This inventor holds 3 USPTO granted patents and 11 published patent applications and 1 EPO patent. Top assignees: Nektar Therapeutics, Schering Corporation. Active years: 2012-2020.
Company Filing History:
Years Active: 2012-2020
Title: Seema Kantak: Innovator in Cancer Treatment
Introduction
Seema Kantak is a notable inventor based in Pacifica, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of new therapeutic methods. With a total of 3 patents, his work focuses on enhancing the efficacy of cancer therapies.
Latest Patents
One of Seema Kantak's latest patents involves IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody. This invention relates to a method of administering treatment to patients suffering from cancer. The method comprises two key steps: (a) administering an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist, and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody. This innovative approach aims to improve patient outcomes in cancer therapy.
Career Highlights
Throughout his career, Seema Kantak has worked with prominent companies in the pharmaceutical industry, including Nektar Therapeutics and Schering Corporation. His experience in these organizations has allowed him to develop and refine his expertise in cancer treatment innovations.
Collaborations
Seema has collaborated with notable professionals in his field, including Murali Krishna Addepalli and Deborah H. Charych. These collaborations have contributed to the advancement of his research and the development of effective cancer therapies.
Conclusion
Seema Kantak's contributions to cancer treatment through his innovative patents and collaborations highlight his commitment to improving patient care. His work continues to influence the field of oncology and offers hope for better therapeutic options in the future.